TherapeuticsMD, Inc. (NASDAQ:TXMD) Sees Large Increase in Short Interest

Posted by Defense World Staff on Nov 15th, 2024

TherapeuticsMD, Inc. (NASDAQ:TXMD – Get Free Report) was the target of a large growth in short interest in October. As of October 31st, there was short interest totalling 29,700 shares, a growth of 26.4% from the October 15th total of 23,500 shares. Based on an average trading volume of 13,700 shares, the days-to-cover ratio is currently 2.2 days. Currently, 0.3% of the shares of the stock are short sold.

Institutional Investors Weigh In On TherapeuticsMD

An institutional investor recently raised its position in TherapeuticsMD stock. Clearline Capital LP raised its stake in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD – Free Report) by 18.9% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 636,622 shares of the company’s stock after buying an additional 101,282 shares during the quarter. Clearline Capital LP owned about 5.52% of TherapeuticsMD worth $1,025,000 at the end of the most recent reporting period. 30.74% of the stock is owned by institutional investors and hedge funds.

TherapeuticsMD Price Performance

Shares of NASDAQ:TXMD opened at $1.46 on Friday. The business’s 50 day simple moving average is $1.62 and its 200-day simple moving average is $1.78. TherapeuticsMD has a 12 month low of $1.43 and a 12 month high of $3.07.

TherapeuticsMD (NASDAQ:TXMD – Get Free Report) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.09) EPS for the quarter. The firm had revenue of $0.23 million for the quarter. TherapeuticsMD had a negative return on equity of 13.90% and a negative net margin of 207.77%.

Wall Street Analysts Forecast Growth

Separately, StockNews.com assumed coverage on TherapeuticsMD in a research note on Saturday, November 9th. They set a “hold” rating on the stock.

View Our Latest Stock Report on TXMD

TherapeuticsMD Company Profile

(Get Free Report)

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.